Last reviewed · How we verify

oxaliplatin, gemcitabine, bevacizumab

Mt. Sinai Medical Center, Miami · Phase 2 active Small molecule

oxaliplatin, gemcitabine, bevacizumab is a Small molecule drug developed by Mt. Sinai Medical Center, Miami. It is currently in Phase 2 development.

At a glance

Generic nameoxaliplatin, gemcitabine, bevacizumab
SponsorMt. Sinai Medical Center, Miami
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about oxaliplatin, gemcitabine, bevacizumab

What is oxaliplatin, gemcitabine, bevacizumab?

oxaliplatin, gemcitabine, bevacizumab is a Small molecule drug developed by Mt. Sinai Medical Center, Miami.

Who makes oxaliplatin, gemcitabine, bevacizumab?

oxaliplatin, gemcitabine, bevacizumab is developed by Mt. Sinai Medical Center, Miami (see full Mt. Sinai Medical Center, Miami pipeline at /company/mt-sinai-medical-center-miami).

What development phase is oxaliplatin, gemcitabine, bevacizumab in?

oxaliplatin, gemcitabine, bevacizumab is in Phase 2.

Related